Ginkgo CADx

Axiomtek launches the newest medical grade artificial intelligence computing system - mBOX100

Retrieved on: 
Wednesday, November 9, 2022
ECC, Sigma 30mm f/1.4 EX DC HSM lens, Software, OEM, David Pakman, Align Technology, TPM, Engineering, NVM Express, ODM, SSD, HDMI, Intel, Data-rate units, OS, Ecosystem, Learning, Linux, PCI Express, Ginkgo CADx, DisplayPort, Temperature, SATA, Intel Core, Efficiency, Solution, IOT, Research, Technology, Medical device, Online shopping

This slim-type medical system complies with the IEC-60601 medical safety standard for use in a variety of hospital applications and healthcare environments.

Key Points: 
  • This slim-type medical system complies with the IEC-60601 medical safety standard for use in a variety of hospital applications and healthcare environments.
  • Aligning with excellent performance, the mBOX100 offers Intel UHD Graphics 620 and 15W TDPs for high-end image processing and provides HDMI and DisplayPort for applications requiring the displays of medical images.
  • This medical AI computing system delivers greater storage with lower latency by a swappable 2.5" SATA III tray with a security lock for SSD and an M.2 Key M 2280 slot for NVMe.
  • As an associate member of the Intel Internet of Things Solutions Alliance, Axiomtek continuously develops and delivers cutting edge solutions based on the latest Intel platforms.

Axiomtek launches the newest medical grade artificial intelligence computing system - mBOX100

Retrieved on: 
Wednesday, November 9, 2022
ECC, Sigma 30mm f/1.4 EX DC HSM lens, Software, OEM, David Pakman, Align Technology, TPM, Engineering, NVM Express, ODM, SSD, HDMI, Intel, Data-rate units, OS, Ecosystem, Learning, Linux, PCI Express, Ginkgo CADx, View, DisplayPort, Temperature, SATA, Intel Core, Efficiency, Solution, IOT, Research, Multimedia, Technology, Medical device, Online shopping

This slim-type medical system complies with the IEC-60601 medical safety standard for use in a variety of hospital applications and healthcare environments.

Key Points: 
  • This slim-type medical system complies with the IEC-60601 medical safety standard for use in a variety of hospital applications and healthcare environments.
  • Aligning with excellent performance, the mBOX100 offers Intel UHD Graphics 620 and 15W TDPs for high-end image processing and provides HDMI and DisplayPort for applications requiring the displays of medical images.
  • This medical AI computing system delivers greater storage with lower latency by a swappable 2.5" SATA III tray with a security lock for SSD and an M.2 Key M 2280 slot for NVMe.
  • Worth mentioning, Axiomtek's mBOX100 has a rugged design with fanless operation for noise-sensitive environments, and antimicrobial coating (optional) as well as white, streamlined design for ideal hospital applications.

Omaha-Based MRI Medical Device Company, Bot Image, Receives FDA Clearance for Artificial Intelligence Software Used in Detection and Diagnosis of Prostate Cancer

Retrieved on: 
Monday, August 8, 2022
FDA, Multimedia, Prostate cancer, Intelligence, Manifest and latent functions and dysfunctions, CAD, CEO, Negotiation, Diagnosis, Technology, Ginkgo CADx, Incontinence, Liver disease, CT, Hospital, Classification, Software as a service, Radiology, Man, Patient, Stroke, Use, Prostate, Contract, Cade, VPN, Artificial intelligence, HIPAA, Software, Time, Development, MRI, Adoption, Medical imaging

OMAHA, Neb., Aug. 8, 2022 /PRNewswire/ -- Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).

Key Points: 
  • OMAHA, Neb., Aug. 8, 2022 /PRNewswire/ -- Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to significantly improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).
  • The tool, called ProstatID, combines artificial intelligence with traditional MRI scanning.
  • "Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone.
  • The Omaha-based medical imaging software company's first product, ProstatID, blends AI with MRI to detect potentially cancerous lesions, assigning a cancer probability score to each, and aid physician's in the patient diagnosis.

Median Technologies Announces 2021 Revenue of €20.5 Million, Up 52%, and a Strengthened Cash Position of €39 Million

Retrieved on: 
Monday, January 17, 2022
Oncology, Medical Devices, Health, Other Health, Pharmaceutical, Biotechnology, Patient, Cade, Cave rescue, Technology, NMPA, Ginkgo CADx, Exercise, Lung cancer screening, CEO, BPI, Solution, Software, Cancer, SME, Malignancy, Lung cancer, Medical device, CT, Artificial intelligence, Diagnosis, Lists of diseases, LCS, FDA, Mission statement, Animal, Medical imaging

As of December 31, 2021, Median Technologies revenue was 20.5 million, a 52% increase compared to 2020 revenue.

Key Points: 
  • As of December 31, 2021, Median Technologies revenue was 20.5 million, a 52% increase compared to 2020 revenue.
  • The company recorded 5.1 million in revenue in Q4 2021, a 24.4% increase compared to Q4 revenue in 2020 (4.1 million).
  • As of December 31, 2021, cash and cash equivalents were 39 million, compared to 16 million as of December 31, 2020.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies Announces Outstanding Lung Nodule Detection (CADe1) Performance for iBiopsy® Lung Cancer Screening

Retrieved on: 
Wednesday, January 5, 2022
Oncology, Medical Devices, Health, Other Health, Pharmaceutical, Biotechnology, Time, NASH, Radiology, CT, AI, Lung, Attention, Euronext Growth, Review, Software, Patient, HCC, Ginkgo CADx, Technology, Lung cancer, Cancer, Lung cancer screening, Prognosis, Artificial intelligence, Algorithm, Data science, Disease, CEO, Biomarker, Precision medicine, SME, FDA, Cade, Diagnosis, Liver cancer, Mortality, DS, LCS, Solution, Liver disease, Fatigue, Malignancy, BPI, Medical imaging

Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.

Key Points: 
  • Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.
  • When screening for lung cancer, the entire lung must be scanned, which can generate hundreds of images for each patient to detect very small lung nodules.
  • The results released today by Median Technologies specifically focus on the lung nodule detection function, which applies Medians proprietary deep learning algorithms to low-dose computed tomography (LDCT).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization

Retrieved on: 
Tuesday, November 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NSCLC, Liver cancer, AI, International Association, Diagnosis, Prognosis, Lung cancer, LCS, EIB, Cade, CEO, RSNA, Cancer, Precision medicine, Liver disease, DS, National Lung Screening Trial, NLST, European Commission Investment Plan for Europe, Death, Research, HCC, BPI, Exhibition, Euronext Growth, Committee on European Affairs and Oversight of the European Funds, Solution, Survival, Radiology, Artificial intelligence, Literature, Ginkgo CADx, FDA, SME, Patient, Adoption, Biomarker, Technology, European Investment Bank, Non-small-cell lung carcinoma, Malignancy, Data science, NASH, AUC, Disease, Medical imaging

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.
  • New results specifically focus on the characterization of stage 1 lung cancer nodules, using Medians proprietary iBiopsy deep learning algorithm on low-dose chest computed tomography (LDCT).
  • Lung cancer is the number one cancer killer globally, causing an estimate of 1.8m deaths, accounting for 18% of all cancer deaths in 20202.
  • A noteworthy International Early Lung Cancer Action Program (I-ELCAP) cohort study of stage 1 cancer patients4 revealed an excellent 15-year LCS survival of 92% which again serves to show how critical early stage diagnosis via lung cancer screening remains.

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Lung cancer, Medical tests, Clinical medicine, Health, Radiology, Lung nodule, Screening, Cancer screening, Cancer, CT scan, Oncology

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.